VanEck Pharmaceutical ETF
PPH
58 hedge funds and large institutions have $108M invested in VanEck Pharmaceutical ETF in 2014 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 3 closing their positions.
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
18% more funds holding
Funds holding: 49 → 58 (+9)
2.71% more ownership
Funds ownership: 30.18% → 32.9% (+2.7%)
11% less capital invested
Capital invested by funds: $121M → $108M (-$13.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AHS
Aspiriant Holdings S3
Los Angeles,
California
|
+$3.87M |
| 2 |
ACM
Aviance Capital Management
Sarasota,
Florida
|
+$2.52M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.32M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.22M |
| 5 |
SG Americas Securities
New York
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$18.6M |
| 2 |
Barclays
London,
United Kingdom
|
-$15.8M |
| 3 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
-$7.32M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.09M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$1.11M |
PPH Hedge Fund Activity: Q4 2014 in Review
58 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2014, worth a combined $108M — down 11% from $121M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PPH positions and 3 closed out — a net gain of 11 holders — while 18 added to existing stakes and 12 trimmed.
The largest buyer was Aspiriant Holdings S3, opening a new position worth an estimated $3.87M. The largest seller was Goldman Sachs, cutting an estimated $18.6M.
- 58 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2014, up from 49 in Q3 2014.
- Funds reported $108M of VanEck Pharmaceutical ETF stock for Q4 2014, down 11% quarter-over-quarter.
- 14 funds opened new VanEck Pharmaceutical ETF positions in Q4 2014 and 3 closed out, a net change of +11 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2014 was Aspiriant Holdings S3, an estimated $3.87M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2014 was Goldman Sachs, an estimated $18.6M sold.
Based on aggregated 13F filings for Q4 2014.